Introduction
Endovascular treatment of symptomatic atherosclerotic peripheral artery disease (PAD) has gained widespread acceptance and is now recommended as the primary revascularization strategy in many clinical and anatomic scenarios. 1 3 Percutaneous transluminal angioplasty (PTA) of the superficial femoral and/or popliteal artery has a high initial success rate, however, restenosis occurs in up to 60% of cases. 4 Although randomized trials have demonstrated patency rates with bare metal stents and drug-eluting stents superior to those observed with PTA, 5 8 the optimal treatment for superficial femoral and/or popliteal artery disease remains controversial.
Some practice guidelines advise against primary stenting in patients with intermittent claudication, 9 while others recommend primary stenting in short-or intermediate-length lesions 3 or in the event of acute PTA failure. 1 2 In spite of the improved outcomes reported in some trials with stenting, the dynamic stresses applied by the superficial femoral and popliteal artery may result in stent fracture 10 11 or in-stent restenosis. 12 Given the limitations of stenting, there has been considerable interest in identifying approaches that could improve patency without the need for a permanent metallic implant.
One approach to this challenge has been the development of the drug-coated balloon (DCB), which combines balloon dilatation with local delivery of an antiproliferative drug. Proofof-concept evidence has demonstrated the utility of different DCB technologies in reducing both restenosis and the need for re-intervention compared with PTA. [13] [14] [15] [16] [17] Promising primary patency and target lesion revascularization rates up to 2-years post-implantation have been reported. 18 However, robust evidence from large randomized controlled trials is lacking. The IN.PACT SFA
Trial was designed to test the safety and efficacy of the IN.PACT Admiral DCB for the treatment of patients with symptomatic PAD in the superficial femoral and/or proximal popliteal artery.
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Both protocols were approved by the institutional review boards or ethics committees at each trial site. All patients provided written informed consent prior to enrollment. Both trial phases were conducted in accordance with the Declaration of Helsinki, good clinical practice guidelines, and applicable laws as specified by all relevant governmental bodies.
An independent clinical events committee adjudicated all major adverse events.
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Patient Population
Patients were eligible for enrollment if they had moderate to severe intermittent claudication or ischemic rest pain (Rutherford 2-4) and stenosis of 70-99% with lesion lengths between 4 and 18 cm or occlusion with lengths of 10 cm involving the superficial femoral and proximal popliteal arteries, and met all other eligibility criteria.
Randomization and Blinding
Randomization occurred after successful crossing of the lesion in the IN.PACT SFA I phase and after successful crossing and pre-dilatation with a standard PTA balloon 1 mm smaller than the reference vessel diameter in the IN.PACT SFA II phase. A patient was considered enrolled at the time of randomization. Subjects were randomized by an Interactive Voice Response System using a method of permuted blocks to assure that a 2:1 ratio was maintained across sites ( Figure 1) .
The patients and the trial sponsor were blinded to the treatment assignments through the completion of all 12-month follow-up evaluations. The independent core laboratories and clinical events committee will remain blinded to the treatment assignments throughout the 60-month follow-up duration. Due to the visual difference between the IN.PACT DCB and standard PTA balloon, treating physicians, research coordinators, and catheterization laboratory staff were not blinded to the treatment assignment. Treating physicians, research coordinators, and catheterization laboratory staff received detailed and specific instructions and training on how to preserve the patients' blinded status.
Treatment and Medical Therapy
Patients randomized to the experimental arm were treated with the IN.PACT Admiral DCB. The The pa ati ti ie e ent t ts a and nd nd t the he he t t tri ri rial al s s spo po pons ns so or r we e ere e e bli ind nd ded d d t to o o th th he tr tre ea atm m men ent t t a as ssi sign gn gnme men n nts s th th hro ro r u ug ugh h h th h he co omp mp mple le leti tion on n o o of f al all l 1 12 12-m -m mo on onth th f f fol ol o lo lo low-w-w-u up up e eva va valu lu luat tio io ions ns s. Th Th he e in in ind de depe pe pend nd den en nt t t co co ore e e l la abo bo b ra ra r to to ori ri ie e es a a and nd d c cl li lin ni ica c events commi mi itt tt t ee ee e w w wil il i l l l re re rema ma main in n b bli li lind nd n ed ed e t t to o o th th the e e tr tr trea ea e tm tm tmen en ent t as as assi si ign gn gnme me ment n n s s s th th thro ro roug ug ugho ho h ut ut ut t t the he he 6 6 60-0 0 month Pre-medication included a loading dose of aspirin 300-325 mg and clopidogrel 300 mg within 24 hours of the index procedure or 2 hours post-procedure. Heparin was administered at the time of the procedure to maintain an activated clotting time 250 seconds. Post-dilatation with a standard PTA balloon was allowed at the discretion of the operator. In both treatment groups, provisional stenting was allowed only in case of PTA failure after repeated and prolonged PTA inflations. PTA failure was defined as a residual stenosis 50% or major ( Grade D) flow-limiting dissection confirmed by a peak translesional systolic pressure gradient >10 mmHg.
In both arms, post-procedure medical therapy included aspirin 81-325 mg daily (for a minimum of 6 months) and clopidogrel 75 mg daily for a minimum duration of 1 month for nonstented patients and 3 months for patients who received stents. Usage of aspirin and anti-platelet drugs did not differ between treatment arms at discharge (97.6%), 30-days (87.6%) or 12 months (51.5%).
Follow-Up
Pre-medication included a loading dose of aspirin 300-325 mg and clopid id dog og gre r l l l 30 For the primary endpoint analysis, patients were followed by the treating physician at 30 days, 6
months, and 12 months, including office visits with duplex ultrasonography functional testing and adverse event assessment. Re-interventions, if required within 12 months of the procedure, were performed according to standard practice using PTA balloons and provisional stenting.
Study Endpoints
The primary efficacy endpoint was primary patency at 12 months following the index procedure, defined as freedom from clinically-driven target lesion revascularization and restenosis as determined by duplex ultrasonography-derived peak systolic velocity ratio 2.4. 
Statistical Analysis
The planned enrollment of 330 subjects provided power of 80% to detect a 50% improvement in the primary endpoint at 12 months (from 40% 4 in the PTA group to 60% in the DCB group) with a 1-sided Type I error of 2.5%. From its inception, the trial was intended to have 2 phases under a single statistical analysis plan. Poolability of subjects across trial phases for the primary endpoint analysis was tested using Cox proportional hazards regression. For this poolability analysis, model covariates included treatment group, phase, and a treatment-by-phase interaction effect. Since the treatment-by-trial phase interaction-value for the primary endpoint was nonsignificant (P =.428), the 2 trial phases were pooled for all analyses.
All analyses were based on the intention-to-treat principle. Continuous variables are described as mean +/-standard deviation and were compared by t-tests. Categorical variables are described as proportions and were compared by the Z-test due to the 1-sided testing. The Z-test was used to test the hypothesis of equality of proportions in achieving the primary endpoint.
Multiple imputation was carried out using the logistic regression approach for patients with missing primary endpoint data (29 DCB, 7 PTA). The following variables were included in the imputation model as covariates: age; gender; diabetes; lesion length; total occlusion; and Rutherford class at baseline. Five data sets were imputed from these covariates that mimic different realizations of the missing data. Within each imputed dataset for the endpoint, the proportion experiencing the endpoint was statistically compared between treatment groups using the 2-sample Z-test. From these, an overall test statistic for the endpoint and its associated Pvalue were calculated for the imputed data. The imputed difference [95% CI] and P-value are reported along with the as-observed numerator and denominator. A sensitivity analysis of the asignificant (P = ( .428), the 2 trial phases were pooled for all analyses.
All analyses were based on the intention-to-treat principle. Continuous variables are de esc sc cri ri ribe be bed d d as as a m m mea ea an n n +/ + -standard deviation and wer er ere c compared by t t t-t -ests ts s. . C C Categorical variables are observed rates revealed a similar highly significant P-value (P<.001). As a secondary analysis, clinically-driven target lesion revascularization was analyzed by the Kaplan-Meier method during the 12-month follow-up period. The difference in the survival curves between groups was assessed using log-rank statistics. Statistical analyses were performed using SAS (SAS Institute, North Carolina USA) version 9.2 or higher. Additional statistical information is found in Supplemental Appendix 1.
Results

Baseline and Procedural Characteristics
Between Figure 1 . Demographics, comorbidities, and lesion characteristics were similar between the DCB and PTA groups ( Table 1) . The mean lesion length was 8.94±4.89 in the DCB arm and 8.81±5.12 cm in the PTA arm (P =.82).
Occlusions were treated in 25.8% and 19.5% (P =.22) of patients in the DCB and PTA arms, respectively. No significant differences across the 2 arms were observed except for a lower number of patent infrapopliteal run-off vessels in the PTA group (P =.04). Adjustment for differences in run-off between the treatment groups using propensity scores had no impact on the primary efficacy and safety outcomes.
Efficacy Outcomes
Procedural success, defined as residual diameter stenosis 50% for non-stented patients or 30%
for stented patients, was achieved in 99.5% of subjects in the DCB arm and 98.2% of subjects in the PTA arm.
In the intention-to-treat population, the 12-month primary patency rate was 82.2% in the DCB arm versus 52.4% in the PTA arm (P <.001) ( Table 2 ). The DCB-treated patients demonstrated lower rates of clinically-driven target lesion revascularization versus PTA-treated patients through 12 months (2.4% vs. 20.6%; P <.001) (Figure 2) . A significantly higher primary sustained clinical improvement (85.2%) was observed in the DCB arm compared with the PTA arm (68.9%) (P <.001). The ABI was significantly higher in the DCB arm at 12 months ( Table 2) . Implantation of provisional stents was similar in the DCB and PTA arms (7.3% versus 12.6%; P=.11). When stented patients were excluded from the analyses, there were no changes in any of the conclusions. Efficacy outcomes by trial phase are included in Supplemental Table 1 .
Safety Outcomes
There were no procedure-or device-related deaths and no major amputations through 12 months in either arm. Site-reported and Clinical Events Committee -adjudicated vessel thrombosis occurred in 1.4% of the subjects in the DCB arm and 3.7% of the subjects in the PTA arm (P =.10). Allcause death through 12 months was 1.9% (N=4) vs. 0.0% (N=0) in the DCB and PTA arms, respectively (P =.93). Causes of death included cerebral infarction at 127 days, biliary sepsis at 168 days, sudden death at 287 days, and a perforated colon at 314 days following the index procedure. There were no untoward paclitaxel-related adverse effects as determined by the Clinical Events Committee. Safety outcomes by trial phase are included in Supplemental Table 1 .
Functional Outcomes
At 12 months, there was no significant difference between treatment groups in the change from baseline in Quality-of-Life using the EQ-5D assessment, but the results trended in favor of 
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Discussion
In this trial, the IN.PACT Admiral drug-coated balloon resulted in superior efficacy when compared to a plain angioplasty balloon for the treatment of patients with symptomatic superficial femoral and/or proximal popliteal PAD. There was significantly better primary patency and a marked reduction in the need for target lesion revascularization at 12 months following treatment with the DCB.
Efficacy of paclitaxel in reducing restenosis in the femoropopliteal artery has been previously reported using different DCB technologies in various trials. [13] [14] [15] [16] [17] [18] While paclitaxel is the most commonly utilized antiproliferative drug in these preceding trials, each DCB was unique with respect to the paclitaxel dose (varying from 2 -3.5 μg/mm 2 ), the carrier molecule (excipient), the balloon material, and the balloon and coating technology employed. The findings from the present trial are consistent with these previous DCB proof-of-concept trials [13] [14] [15] [16] which, although smaller because powered on a 6-month angiographic endpoint, enrolled a similar patient population with symptomatic femoropopliteal disease. All of these trials demonstrated significant reductions in late lumen loss at 6 months and lower rates of target lesion n this trial, the IN.PACT Admiral drug-coated balloon resulted in superior effic ca a acy y y wh wh when en en compared to a plain angioplasty balloon for the treatment of patients with symptomatic u upe pe perf rf rfic ic icia ia ial l l fe fe femo mora ra ral l l a and/or proximal popliteal PA A AD. D. D There was sig g gni n fica ca an nt ntly better primary pate e enc n y and a a m ma ar rk ked ed d red ed educ ucti ti tio on on i in n n t th the e n ne eed d fo o or ta arg rg get l l le es sio ion n n r re rev va as sc cul ular ar riz z zat atio io on n n at at 1 1 12 2 2 mo mo mont nt th hs hs fo oll ll llow ow owin in i g g g tr tr trea e eatm tm men n nt t w w with th h t the he D DCB CB CB. .
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These findings compare favorably with other randomized clinical trials in this patient population. Despite inclusion of longer lesion lengths that are at a higher risk of treatment failure, the 2.4% target lesion revascularization rate experienced in this trial is the lowest reported for an SFA device trial at 12 months. Clinically-driven target lesion revascularization rates of 12.7% and 9.5% were reported in 2 recent randomized trials of bare metal and drug eluting stents, despite their inclusion of shorter lesions (average lesion lengths of 7.0 and 5.4 cm, fatigue may lead to stent fracture and increased risk of in-stent restenosis. 10 11 R Re e este te eno o osi si s s s s following superficial femoral and/or popliteal artery stenting has been reported to occur in recent r ria ials ls ls w w wit it ith h h a a a fr f freq que ue uenc n y of about 20% at 12 month th hs s w w with highe a r ra ate te es of of f u u up p p to 50% following t ten n nti t ng of long ng--se e egm me ent nt nt d d di is isea ea ease se. years, thoug gh h re re rece ce ent nt nt r res es esul u ts ts s h h hav av ave e e su su sugg g g es es este te ed d d im im impr pr prov ov oved ed ed o out ut utco co come me mes s s wi wi w th th th p p per er erip ip iphe he h ra ra al l l dr dr drug ug ug-e -luting respectively). [7] [8] IN.PACT DCB was associated with a low complication rate, including the absence of major amputations and a low rate of vessel thrombosis.
Study Limitations
The trial was deliberately and prospectively conducted in 2 sequential phases. The blinding of phase I was rigorously maintained until the completion of phase II. When the data were analysed, there were no statistical differences between the 2 phases.
Although improvements in the functional assessments of Quality-of-Life, walking impairment, and walking distance were observed in both treatment groups, the interpretation of these measures is complicated by the subjective nature of patient questionnaires and the influence of comorbidities, including progressive disease in non-treated vessels.
The results of this trial cannot be generalized to patients not included in this trial. Future studies should encompass longer lesions and consider comparison with bare metal stents, drugeluting stents, and bypass, as well as optimal medical therapy and exercise. Longer term followup is needed to confirm the durability of the benefit
Conclusions
In conclusion, in this large, prospective, multicenter, international, randomized trial, DCB was superior to PTA and had a favorable safety profile for the treatment of patients with symptomatic Proximal Pop opli li lite te t al al l I Inv nvol ol lve veme ment nt -% % % (m (m/n / /n) ) ) 6. 6. Successful delivery, inflation, deflation, and retrieval of the intact trial balloon without burst < rated burst pressure; § § No procedural complications (death, major target limb amputation, thrombosis of target lesion, or target vessel revascularization (TVR)) prior to discharge; |||| Residual diameter stenosis 50% for nonstented subjects or 30% for stented subjects.
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